AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30414841
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections into epicardial fat pads
Trial: 30414841
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (BTX) injections
Trial: 21817198
Drug: NVP XR
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NVP XR 400 mg once daily (plus placebo)
Trial: 21817198
Drug: NVP IR
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NVP IR 200 mg twice daily (plus placebo)
Trial: 19565730
Drug: Acupoint application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint application using Chinese medicine (Zhinanxing, Sanleng, Ezhu) at Zhongji (CV 3), Guanyuan (CV 4), Qihai (CV 6)
Trial: 19565730
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Tianqi Tongjing Capsules
Trial: 15624744
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg subcutaneous efalizumab weekly for 12 weeks
Trial: 15624744
Drug: Maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance treatment with weekly SC efalizumab after Week 12
Trial: 15624744
Drug: Extended efalizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended efalizumab therapy
Trial: 27725248
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg fludrocortisone, a MR agonist
Trial: 25435850
Drug: Gemcitabine 1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1250 mg/m2 (standard half hour i.v. infusion on days 1 and 8) + Cisplatin 75 mg/m2 on day 2
Trial: 25435850
Drug: Gemcitabine 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 250 mg/m2 (prolonged 6-hours i.v. infusion on days 1 and 8) + Cisplatin 75 mg/m2 on day 2
Trial: 19346279
Drug: Pregabalin (150-450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (150-450 mg)
Trial: 9863127
Drug: Xinmaitong Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinmaitong Capsule (XMTC)
Trial: 9863127
Drug: Composite Danshen
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite Danshen Tablet (CDT)
Trial: 23013888
Drug: Olmesartan (morning-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan (morning-dose group)
Trial: 23013888
Drug: Olmesartan (evening-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan (evening-dose group)
Trial: 19682654
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment initiated at the earliest possible stage post injury
Trial: 17062304
Drug: Tizanidine capsules
RxNorm normalized name: Tizanidine Capsules
DrugBank: Tizanidine (DB00697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tizanidine capsules (8 mg) administered with food
Trial: 17062304
Drug: Tizanidine tablets
RxNorm normalized name: Tizanidine Tablets
DrugBank: Tizanidine (DB00697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tizanidine tablets (8 mg) administered with food
Trial: 17062304
Drug: Tizanidine capsules
RxNorm normalized name: Tizanidine Capsules
DrugBank: Tizanidine (DB00697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tizanidine capsules (8 mg) administered in fasting state
Trial: 17062304
Drug: Tizanidine tablets
RxNorm normalized name: Tizanidine Tablets
DrugBank: Tizanidine (DB00697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tizanidine tablets (8 mg) administered in fasting state
Trial: 12932798
Drug: Pemoline (56.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemoline (56.25 mg)
Trial: 10636414
Drug: Insulin 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin 1.5 mU/kg per minute
Trial: 10636414
Drug: Insulin 3
RxNorm normalized name: Pen Needle Insulin 33 gauge 4mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin 3 mU/kg per minute
Trial: 8864546
Drug: Intranasal pretreatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal pretreatment with NPY (20 nmol)
Trial: 1346819
Drug: Antiphospholipid antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiphospholipid antibodies (aCEPHA and aCL)
Trial: 6397949
Drug: Incision plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incision plus curettage and primary suture under antibiotic cover
Trial: 29364026
Drug: 4-week progressive
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week progressive home intrinsic foot muscle (IFM) exercise program performed daily
Trial: 28419379
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of local anesthetic to myofascial trigger points (MTrPs)
Trial: 15543337
Drug: B-vitamins (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-vitamins (5 mg folic acid, 0.4 mg hydroxycobalamin and 50 mg pyridoxine) daily for 8 weeks
Trial: 9124839
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (1,000 mg)
Trial: 2174933
Drug: Symptomatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic treatment (group 2)
Trial: 7013960
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with diethylstilbestrol, cyclophosphamide, and 5‐fluorouracil (DES + CTx + FU)
Trial: 7013960
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (DES leads to CTx + FU)
Trial: 22456300
Drug: semagacestat 140
RxNorm normalized name: Semagacestat
DrugBank: Semagacestat (DB12463)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semagacestat 140 mg
Trial: 22456300
Drug: semagacestat 280
RxNorm normalized name: Semagacestat
DrugBank: Semagacestat (DB12463)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semagacestat 280 mg
Trial: 10440399
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) treatment aimed at three predefined target MPA AUC values (16.1, 32.2, and 60.6 microg x hr/ml)
Trial: 1980464
Drug: All drugs
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All drugs (Lormetazepam and Flurazepam)
Trial: 28865911
Drug: Trauma Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma Management Therapy (TMT; VRET plus a group treatment for anger, depression, and social isolation)
Trial: 29336615
Drug: Ornibel® (etonogestrel/ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornibel® (etonogestrel/ethinylestradiol 11.00/3.47 mg)
Trial: 29336615
Drug: Nuvaring® (etonogestrel/ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nuvaring® (etonogestrel/ethinylestradiol 11.7/2.7 mg)
Trial: 23812209
Drug: NexGen LPS
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NexGen LPS Gender Solutions (GS) prosthesis
Trial: 19493153
Drug: ICD plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD plus appropriate medical therapy
Trial: 17074344
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (0.2 mg)
Trial: 12101821
Drug: Regular exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular exercise and low fat diet (walking 60 minutes daily, <20% total fat, 300 mg/d cholesterol)
Trial: 9773699
Drug: ISBPB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISBPB with 10 mL 0.125% bupivacaine with epinephrine 1:400,000 (n = 15)
Trial: 9791777
Drug: Standard approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard approach to postoperative analgesia (intramuscular injections on an 'as needed' basis)
Trial: 410298
Drug: Low-dose Rho(D)
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Rho(D) immune globulin (human)
Trial: 410298
Drug: Single low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single low-dose immune globulin preparations
Trial: 26361969
Drug: Sorafenib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (400 mg oral, twice a day for a maximum of 4 years)
Trial: 26361969
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice a day for a maximum of 4 years)
Trial: 23574730
Drug: Miglitol (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglitol (150 mg/day)
Trial: 18449573
Drug: Double lumen
RxNorm normalized name: SOLUPICC 7-Day Double Lumen PICC Line Supply Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double lumen totally implantable subcutaneous port system (PORT)
Trial: 17109447
Drug: Cisplatin (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (35 mg/m2) and gemcitabine (1000 mg/m2) with paclitaxel (70 mg/m2)
Trial: 17109447
Drug: Cisplatin (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (35 mg/m2) and gemcitabine (1000 mg/m2) with vinorelbine (25 mg/m2)
Trial: 11723527
Drug: Budesonide 400
RxNorm normalized name: Budesonide 400 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 400 microg administered twice daily via a breath‐activated, multi‐dose, dry‐powder inhaler
Trial: 2730857
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of total doses delivered
Trial: 30133324
Drug: Mice undergoing
RxNorm normalized name: Douxo Micellar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mice undergoing reloading after hindlimb suspension.
Trial: 21538524
Drug: Levetiracetam (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (up to 2000 mg per day)
Trial: 14520143
Drug: Linezolid 10
RxNorm normalized name: LINEZOLID 100MG/5ML SUSP,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid 10 mg/kg iv every 8 h (with option to switch to oral linezolid 10 mg/kg every 8 h)
Trial: 14520143
Drug: Vancomycin 10
RxNorm normalized name: vancomycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 10 to 15 mg/kg every 6 to 24 h
Trial: 11090730
Drug: succinylcholine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: succinylcholine 1.5 mg/kg
Trial: 11090730
Drug: rocuronium bromide
RxNorm normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rocuronium bromide 0.6 mg/kg
Trial: 8982415
Drug: Tap water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tap water iontophoresis in addition to two-sided steroid-free topical therapy
Trial: 31091508
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine (0.6 mg/kg)
Trial: 28779006
Drug: TREX dosing
RxNorm normalized name: L-m-trex
DrugBank: CH-1504 L-isomer (DB19052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TREX dosing
Trial: 28779006
Drug: Monthly dosing
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly dosing transitioned to PRN
Trial: 27599170
Drug: Massage with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage with lotion
Trial: 27599170
Drug: Massage without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Massage without lotion
Trial: 24667391
Drug: High-dose remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose remifentanil (1.2 μg kg(‐1) min(‐1))
Trial: 24667391
Drug: Regular dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular dose remifentanil (0.2 μg kg(‐1) min(‐1))
Trial: 22464116
Drug: Pilates-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilates-based therapy
Trial: 31525673
Drug: Active control
RxNorm normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active control condition (n = 50) consisting of 24 one-hour sessions addressed twice a week
Trial: 29056103
Drug: Targeted dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted dietary advice solutions developed per metabotype using a decision tree approach.
Trial: 21102369
Drug: Topical proparacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical proparacaine
Trial: 11448899
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 25 mg HRS‐3/A9 for 4 days
Trial: 11448899
Drug: 1-hour infusion
RxNorm normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hour infusion of 25 mg HRS‐3/A9 every other day
Trial: 11448899
Drug: HRS‐3/A9 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS‐3/A9 treatment
Trial: 9602194
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (≤ 20 ppm for 1 to 4 days)
Trial: 2662065
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release naproxen (Naprosyn CR), 750 mg daily
Trial: 2662065
Drug: Standard Naprosyn,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Naprosyn, 750 mg daily
Trial: 23649997
Drug: Radiotherapy combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy combined with temozolomide (TMZ) - 200 mg/m² for 5 days post-surgery, followed by 75 mg/m² daily during radiotherapy, and 150-200 mg/m² for 5 days every 28 days after radiotherapy.
Trial: 23649997
Drug: Radiotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy alone - involved-field radiotherapy in 2 Gy fractions daily for 6 weeks (total of 60 Gy).
Trial: 16809799
Drug: Lanthanum chloride
RxNorm normalized name: LANTHANUM CHLORIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanthanum chloride (LaCl3) intravenous infusion (120 microg elemental lanthanum over a 4-hour period)
Trial: 16809799
Drug: Chewable lanthanum
RxNorm normalized name: lanthanum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewable lanthanum carbonate (La2(CO3)3) tablets (1-g oral dose; 4 x 250 mg elemental lanthanum)
Trial: 9284854
Drug: Indomethacin (0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (0.20 mg/kg every 12 hours) + Furosemide (1 mg/kg)
Trial: 9284854
Drug: Indomethacin (0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (0.20 mg/kg every 12 hours)
Trial: 3455968
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of AA per day for two weeks
Trial: 3455968
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg (placebo) per day for four weeks
Trial: 3455968
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg per day for three weeks
Trial: 3455968
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg per day for four weeks
Trial: 15752096
Drug: Zinc tablets
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc tablets
Trial: 15752096
Drug: Chlorhexidine tablets
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine tablets and mouthwash
Trial: 12677364
Drug: Cyclosporine-based immunosuppressive
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine-based immunosuppressive therapy
Trial: 8799424
Drug: RO‐11 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO‐11 at a daily s.c. dose of 2,500 anti‐FXa IU
Trial: 8799424
Drug: Calcium unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium unfractionated heparin (UH) at a s.c. dose of 5,000 IU 12 hourly
Trial: 1453197
Drug: Baseline and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline and change in scores for physical well-being (PWB), mood, pain, and QLI after the first three treatment cycles
Trial: 6606942
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of saline placebo
Trial: 31006282
Drug: 2-hourly static
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-hourly static oral misoprostol
Trial: 25847293
Drug: Usual Care:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual Care: standard intervention provided by the quitline, including brief counseling and nicotine replacement therapy
Trial: 20349229
Drug: Calcium 1,000
RxNorm normalized name: Calcium 1,000mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium 1,000 mg for 1 week followed by Vitamin D3 1,000 i.u. daily for 7 weeks
Trial: 20349229
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 1,000 i.u. daily for 7 weeks followed by Calcium 1,000 mg for 1 week
Trial: 15777441
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose vaginal misoprostol 25 microg every 4 hours (maximum of six doses)
Trial: 15777441
Drug: Dinoprostone vaginal
RxNorm normalized name: dinoprostone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinoprostone vaginal gel 1‐2 mg 6 hourly (maximum of 3 mg in 24 hours)
Trial: 15777441
Drug: Dinoprostone vaginal
RxNorm normalized name: dinoprostone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinoprostone vaginal gel
Trial: 2691106
Drug: Compound five-Shen
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound five-Shen herbal drink (CFSHD) - Group I
Trial: 2691106
Drug: Compound five-Shen
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound five-Shen herbal drink (CFSHD) - Group II
Trial: 23670576
Drug: Endostar (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endostar (7.5 mg/m²) plus dacarbazine (250 mg/m²)
Trial: 23670576
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus dacarbazine (250 mg/m²)
Trial: 21031343
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with fixed dose of 4 mg rosiglitazone plus 500 mg metformin (RSG+MET group, n = 70)
Trial: 21031343
Drug: Half-maximum dose
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Half-maximum dose of metformin monotherapy (MET group, n = 70)
Trial: 8879373
Drug: Chemotherapy (sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (sequential 5‐fluorouracil/leucovorin combined with etoposide or FLv for elderly/poor performance patients)
Trial: 2049700
Drug: Insulin use
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin use among diagnosed diabetics
Trial: 6362699
Drug: Nitrazepam 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrazepam 5.0 mg
Trial: 26443019
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg zinc tablets daily for 12 months
Trial: 26443019
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets daily for 12 months
Trial: 22152099
Drug: High-density negative
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-density negative ion (HDNI) treatment
Trial: 20546266
Drug: Medication possession
RxNorm normalized name: ZINC OXIDE 17.5 g in 100 g TOPICAL LIPSTICK [Lipshade SPF 30 Obsessed]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication possession ratio (MPR)
Trial: 20546266
Drug: Morisky Medication-taking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morisky Medication-taking Scale
Trial: 20546266
Drug: Medication-taking item
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication-taking item of the Summary of Diabetes Self-Care Activities (SDSCA)
Trial: 18056491
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (20 digits)
Trial: 18056491
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection (15 digits)
Trial: 16211735
Drug: Etomidate (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (0.2 mg kg[-1])
Trial: 16211735
Drug: Propofol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2 mg kg[-1])
Trial: 11945098
Drug: Remacemide hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remacemide hydrochloride 1200 mg/day